Probucol restores the defective leukocyte-endothelial interaction in experimental diabetesZANARDO, Renata C. O; CRUZ, José W. M. C; MARTINEZ, Luis L et al.European journal of pharmacology. 2003, Vol 478, Num 2-3, pp 211-219, issn 0014-2999, 9 p.Article

Viability of Developing CETP InhibitorsSIRTORI, Cesare R; MOMBELLI, Giuliana.Cardiovascular therapeutics (Print). 2008, Vol 26, Num 2, pp 135-146, issn 1755-5914, 12 p.Article

AGI-1067 : A novel vascular protectant for prevention of restenosisFRANKS, Amy M; GARDNER, Stephanie F.The Annals of pharmacotherapy. 2006, Vol 40, Num 1, pp 66-73, issn 1060-0280, 8 p.Article

Probucol inhibits ABCA1-mediated cellular lipid effluxFAVARI, Elda; ZANOTTI, Ilaria; ZIMETTI, Francesca et al.Arteriosclerosis, thrombosis, and vascular biology. 2004, Vol 24, Num 12, pp 2345-2350, issn 1079-5642, 6 p.Article

Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathwayYANG, Yun-Bo; YANG, Yi-Xin; BO SU et al.European journal of pharmacology. 2007, Vol 570, Num 1-3, pp 125-134, issn 0014-2999, 10 p.Article

SAFETY AND EFFICACY OF PROBUCOL DURING ONE YEAR OF ADMINISTRATION = L'INNOCUITE ET L'EFFICACITE DU PROBUCOL AU COURS D'UNE ANNEE D'ADMINISTRATIONNASH DT.1974; J. CLIN. PHARMACOL.; U.S.A.; DA. 1974; VOL. 14; NO 8-9; PP. 470-475; BIBL. 9REF.Article

LONG-TERM ORAL ADMINISTRATION OF PROBUCOL (4,4PRIME -(ISOPROPYLIDENEDITHIO) BIS (2,6-DI-T-BUTYLPHENOL)) (DH-581) IN THE MANAGEMENT OF HYPERCHOLESTEROLEMIA = ADMINISTRATION ORALE A LONG TERME DE PROBUCOL PENDANT LE TRAITEMENT DE L'HYPERCHOLESTEROLEMIEHARRIS RS JR; GILMORE HR III; BRICKER LA et al.1974; J. AMER. GERIATR. SOC.; U.S.A.; DA. 1974; VOL. 22; NO 4; PP. 167-175; BIBL. 13REF.Article

Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbitsJEON, Seon-Min; BOK, Song-Hae; JANG, Moon-Kyoo et al.Clinica chimica acta. 2002, Vol 317, Num 1-2, pp 181-190, issn 0009-8981Article

Formation of malonaldehyde in the presence of probucol, an anti-atherosclerosis drugMIYAKE, T; SHIBAMOTO, T.Food and chemical toxicology. 1998, Vol 36, Num 9-10, pp 841-847, issn 0278-6915Article

Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in ratsSO YOUN PARK; JEONG HYUN LEE; CHI DAE KIM et al.Brain research. 2007, Vol 1157, pp 112-120, issn 0006-8993, 9 p.Article

Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanismHIRANO, Ken-Ichi; IKEGAMI, Chiaki; UEDA, Yukihiko et al.Arteriosclerosis, thrombosis, and vascular biology. 2005, Vol 25, Num 11, pp 2422-2427, issn 1079-5642, 6 p.Article

Enzymatic characterization of lipid-based drug delivery systemsLJUSBERG-WAHREN, Helena; NIELSEN, Flemming Seier; BROGARD, Mattias et al.International journal of pharmaceutics. 2005, Vol 298, Num 2, pp 328-332, issn 0378-5173, 5 p.Conference Paper

Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugsIKEDA, Toshio; SAKURAI, Jun; NAKAYAMA, Daisuke et al.American journal of hypertension. 2004, Vol 17, Num 6, pp 502-506, issn 0895-7061, 5 p.Article

Liver Histology Changes in Nonalcoholic Steatohepatitis after One Year of Treatment with ProbucolMERAT, Shahin; ADULI, Mohsen; KAZEMI, Rozana et al.Digestive diseases and sciences. 2008, Vol 53, Num 8, pp 2246-2250, issn 0163-2116, 5 p.Article

Effect of probucol on the oral bioavailability of cyclosporine ASUGIMOTO, Koh-Ichi; SUDOH, Toshiaki; TSURUOKA, Shuichi et al.European journal of pharmaceutical sciences. 2004, Vol 22, Num 1, pp 71-77, issn 0928-0987, 7 p.Article

VII. INTERNATIONAL SYMPOSIUM ON DRUGS AFFECTING LIPID METABOLISM HELD IN MILAN, ITALY MAY 28-31, 1980KRITCHEVSKY D ED; DAY CE ED.1982; ARTERY; ISSN 0098-6127; USA; DA. 1982; VOL. 10; NO 1; 63 P.; BIBL. DISSEM.Conference Paper

Probucol and succinobucol in atrial fibrillation: Pros and consTONG LIU; GUANGPING LI.International journal of cardiology. 2010, Vol 144, Num 2, pp 295-296, issn 0167-5273, 2 p.Article

Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerolsCHRISTENSEN, Janne Ørskov; SCHULTZ, Kirsten; MOLLGAARD, Birgitte et al.European journal of pharmaceutical sciences. 2004, Vol 23, Num 3, pp 287-296, issn 0928-0987, 10 p.Article

Plasma lipoproteins are required for both basal and stress-induced adrenal glucocorticoid synthesis and protection against endotoxemia in miceHOEKSTRA, Menno; KORPORAAL, Suzanne J. A; ZHAOSHA LI et al.American journal of physiology. Endocrinology and metabolism. 2010, Vol 62, Num 6, issn 0193-1849, E1038-E1043Article

Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixturePONGPEERAPAT, Adchara; WANAWONGTHAI, Chalermphon; TOZUKA, Yuichi et al.International journal of pharmaceutics. 2008, Vol 352, Num 1-2, pp 309-316, issn 0378-5173, 8 p.Article

Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixtureWANAWONGTHAI, C; PONGPEERAPAT, A; HIGASHI, K et al.International journal of pharmaceutics (Print). 2009, Vol 376, Num 1-2, pp 169-175, issn 0378-5173, 7 p.Article

Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetesNOMURA, Shosaku; TAKAHASHI, Nobuyuki; INAMI, Norihito et al.Atherosclerosis. 2004, Vol 174, Num 2, pp 329-335, issn 0021-9150, 7 p.Article

Effects of candesartan and probucol on restenosis after coronary stenting: Results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trialWAKEYAMA, Takatoshi; OGAWA, Hiroshi; IIDA, Hiroshi et al.Circulation journal. 2003, Vol 67, Num 6, pp 519-524, issn 1346-9843, 6 p.Article

Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease: The Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) TrialMASSBERG, Steffen; BYRNE, Robert A; LAUGWITZ, Karl-Ludwig et al.Circulation (New York, N.Y.). 2011, Vol 124, Num 5, pp 624-632, issn 0009-7322, 9 p.Article

Antioxidants: Benefits and risks for long-term healthYOSHIHARA, Daisaku; FUJIWARA, Noriko; SUZUKI, Keiichiro et al.Maturitas (Amsterdam). 2010, Vol 67, Num 2, pp 103-107, issn 0378-5122, 5 p.Article